Corporate Banner
Satellite Banner
Genotyping & Gene Expression
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Personalized Medicine Coalition Announces Two New Board Members

Published: Thursday, December 12, 2013
Last Updated: Thursday, December 12, 2013
Bookmark and Share
Appointments deepen expertise in drug development, payer community.

The Personalized Medicine Coalition (PMC) has announced the appointment of Steven D. Averbuch, M.D., Vice President, Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb and Michael Kolodziek, M.D., National Medical Director, Oncology Solutions, Office of the Chief Medical Officer, Aetna to the Coalition's board of directors for a three-year term beginning November 2013.

"With the election of these two leaders in personalized medicine - one a drug developer and the other from the payer community - PMC is well positioned to help define the future of medical progress," said Edward Abrahams, Ph.D., President, PMC.

"Over the years, the PMC has been a leader in creating awareness, facilitating stakeholder dialogue and providing roadmaps toward establishing a health care system that embraces personalized medicine," says Averbuch. "It is clear that the PMC membership is working toward a common goal to improve patient outcomes and I am honored to be given the opportunity to contribute toward this goal as a member of the Board."

In his role with Bristol-Myers Squibb, Averbuch works to optimize knowledge sharing and biomarker tools across all of R&D and is responsible for executing the integrated co-development of diagnostic tests as companions to the company's products.

Averbuch previously held senior level R&D positions at Merck Research Laboratories, AstraZeneca, and Mount Sinai School of Medicine. He has authored more than 60 peer-reviewed publications and book chapters, and is the co-author on one patent.

Kolodziej leads the strategic development, design and implementation of Aetna's evidence-based, patient-focused cancer care programs. Previous positions include partner at New York Oncology, chairman of the US Oncology Pharmacy and Therapeutics Committee, and Medical Director for Oncology Services for US Oncology.

Kolodziej has published several manuscripts and given many presentations on cost of cancer care, oncology reimbursement reform, and use of evidence based treatment guidelines to control cost care in oncology.

"I am honored to serve on the board of the Personalized Medicine Coalition. Personalized medicine has the potential to revolutionize health care. We will enter a new era where care is truly patient-focused and patient-specific. The Personalized Medicine Coalition will be a leader in charting the course," says Kolodziej.

The appointments are in conjunction with the expiring terms of Joanne Armstrong, M.D., M.P.H., Aetna, and Nancy Simonian, M.D., Syros Pharmaceutical Inc., who will rotate off the board at year-end 2013.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More than 3,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

PMC to Recognize NIH Director with Leadership in Personalized Medicine Award
Dr. Francis S. Collins to accept award, deliver comments during 11th Annual Personalized Medicine Conference at Harvard Medical School.
Friday, August 28, 2015
PMC Board Continues to Cultivate Leadership from Across Health Care System
Appointments afford additional representation for both diagnostic, therapeutic communities.
Saturday, June 06, 2015
PMC Applauds Margaret Hamburg's Commitment to Personalized Medicine
Hamburg's announced resignation follows the agency's most productive year for personalized medicine novel new drug approvals.
Friday, February 06, 2015
PMC Recognizes Mark Levin with Award for Leadership
Award to be presented November 12, 2014 highlights lifelong personalized medicine vision.
Wednesday, September 17, 2014
Personalized Medicine Coalition Elects New Board Member
Patrick J. Balthrop was elected to the Coalition's board of directors.
Friday, June 21, 2013
PMC Urges FDA to Clarify Rules for Drug-Diagnostic Combinations
PMC urges the agency to clarify its requirements for approving drug-diagnostic combinations.
Thursday, December 24, 2009
Personalized Medicine Coalition Publishes the Case for Personalized Medicine
The 2nd edition of PMC’s landmark report provides a comprehensive overview and analysis of the state of personalized medicine.
Thursday, May 21, 2009
HHS Secretary Leavitt Receives Personalized Medicine Coalition Award for Leadership
The annual PMC award recognizes the contributions of Secretary Leavitt in advancing the frontier of personalized medicine.
Wednesday, November 12, 2008
Personalized Medicine Coalition Applauds New Report
A new report by a presidential advisory council says that personalized medicine—treatment based on an understanding of each patient’s unique physical makeup, including genetic structure—could significantly improve healthcare.
Wednesday, October 15, 2008
PMC Endorses Democratic and Republican Positions on Personalized Medicine
PMC has applauded statements issued by both parties’ campaigns endorsing the principles of personalized medicine and its role in improving healthcare.
Tuesday, September 16, 2008
Personalized Medicine Coalition Applauds Senate Approval of the Genetic Information Nondiscrimination Act
GINA will protect individuals against possible misuse of genetic information and accelerate the adoption of personalized medicine.
Friday, April 25, 2008
Dr. Ralph Snyderman Receives 2007 Leadership in Personalized Medicine Award
Dr. Snyderman, Chancellor Emeritus, Duke University, and Founder and Chairman of Proventys, receives the award for his efforts in advancing predictive and targeted therapies on a national scale.
Friday, November 30, 2007
Personalized Medicine Coalition Supports President Bush's Call to Congress to Pass the Genetic Information Nondiscrimination Act
PMC believes that all genetic information, including family history, deserves strong and enforceable protections against misuse in health insurance and employment.
Friday, January 19, 2007
Scientific News
Poor Survival Rates in Leukemia Linked to Persistent Genetic Mutations
For patients with an often-deadly form of leukemia, new research suggests that lingering cancer-related mutations – detected after initial treatment with chemotherapy – are associated with an increased risk of relapse and poor survival.
Marijuana Genome Unraveled
A study by Canadian researchers is providing a clearer picture of the evolutionary history and genetic organization of cannabis, a step that could have agricultural, medical and legal implications for this valuable crop.
Growing Hepatitis C in the Lab
Recent discovery allows study of naturally occurring forms of hepatitis C virus (HCV) in the lab.
Signature of Microbiomes Linked to Schizophrenia
Studying microbiomes in throat may help identify causes and treatments of brain disorder.
Study Identifies the Off Switch for Biofilm Formation
New discovery could help prevent the formation of infectious bacterial films on hospital equipment.
Genetic Overlapping in Multiple Autoimmune Diseases May Suggest Common Therapies
CHOP genomics expert leads analysis of genetic architecture, with eye on repurposing existing drugs.
Fat in the Family?
Study could lead to therapeutics that boost metabolism.
Combo Tool
Joining molecular components expands ability to manipulate genes in specific cell types.
Team Identifies Structure of Tumor-Suppressing Protein
An international group of researchers led by Carnegie Mellon University physicists Mathias Lösche and Frank Heinrich have established the structure of an important tumor suppressing protein, PTEN.
Genes Associated With Improved Survival for Pancreatic Cancer Patients
Use of non-invasive liquid biopsies could predict in which patients the cancer could recur following surgery.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!